ReachMD

This upcoming live webinar will review the mechanisms linking adipose tissue dysfunction to hepatic steatosis and fibrosis, while examining practical approaches to identifying patients who may benefit from MASLD evaluation. Find a broadcast that fits your schedule: ow.ly/l3OU5102CvV #MASLD #Obesity #MetabolicDysfunction #Hepatology

CME Dinner Tomorrow. Which path will YOU choose? Join us in Philadelphia for an interactive Choose Your Own Adventure™ CME dinner symposium. Vote LIVE as expert faculty guide you through real-world patient cases, evolving treatment options, and critical decisions that shape TED care. Don't miss this unique CME experience! Register for the in-person event or virtual broadcast: ow.ly/GuXR51018FC A CME/CE-accredited activity developed by GLC. #TED #ThyroidEyeDisease #MedEd #CME

WHAV 2026 is coming to New York in one month. Join us December 4 at the Sheraton New York Times Square Hotel for the Women’s Health Annual Visit, a full day of expert-led, evidence-based education from world-renowned faculty and clinicians. Save your seat today: ow.ly/cShz5102Eln #WHAV2026 #WomensHealth #MedicalEducation #CME #NYC

How do age and body weight influence sparsentan dosing in patients with FSGS? Hear an expert explain the weight-based starting doses and titration considerations for eligible patients aged 8 years and older. Check out the full program: ow.ly/ybhJ5102Gi9 #FSGS #Nephrology #Sparsentan #MedicalEducation

First-line treatment of KRAS G12C-mutated NSCLC is evolving. Is your practice keeping pace? Join Timothy F. Burns, MD, PhD, thoracic oncologist and lung cancer researcher at the Ohio State University Comprehensive Cancer Center, LIVE for "Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care." 📅 November 9, 2026 🕕 7:00–7:45 PM EDT Dr. Burns will connect the underlying biology of KRAS G12C–mutated advanced NSCLC to real clinical decision-making, giving you a clear framework to apply in first-line treatment. Register for the virtual broadcast now: ow.ly/JqPA510178y A CME/CE-accredited activity developed by GLC. #LungCancer #NSCLC #MedEd

This upcoming live broadcast will explore how metabolic dysfunction links to obesity and MASLD, highlighting how excess visceral fat contributes to MASLD progression and increased cardiometabolic risk. Register now: ow.ly/AGLz5102C8z #Obesity #MASLD #MetabolicHealth #MedicalEducation

Two weeks until WHAV 2026 in Pasadena. Join co-chairs Anita L. Nelson, MD, and Barbara Dehn, WHNP-BC, plus expert faculty on November 13 for a full day of evidence-based education in women's health. Attend in person at the Pasadena Convention Center or join the live broadcast online. Register now: ow.ly/Yxg35102cOH #WHAV2026 #WomensHealth #MedicalEducation #CME #OBGYN #Pasadena

Your patient. Your decisions. Which path will YOU choose? Join us Nov 6 in Philadelphia for an interactive Choose Your Own Adventure™ CME dinner symposium. Vote LIVE as expert faculty guide you through real-world patient cases, evolving treatment options, and critical decisions that shape TED care. Don't miss this unique CME experience! Save your seat for the in-person event or virtual broadcast: ow.ly/HK7251018B5 A CME/CE-accredited activity developed by GLC. #ThyroidEyeDisease #MedEd #TEDCare #CME

LAST CHANCE to join Marc Oliva as he translates the latest perioperative immunotherapy data into practical strategies for resectable, locally advanced HNSCC. The session features clinical trial updates, treatment sequencing considerations, and interactive case discussions. Register now before it's too late: ow.ly/TkBY50ZBA6e A CME/CE-accredited activity developed by GLC. #HNSCC #Oncology #Immunotherapy #CME

What does FDA approval of sparsentan mean for FSGS management? Hear a nephrologist discuss this treatment option and the clinical trial evidence surrounding proteinuria reduction. Discover more: ow.ly/qWYV5101nNP #FSGS #Nephrology #KidneyDisease #MedicalEducation

TED care involves complex decisions across the patient journey. Join our interactive, case-based dinner symposium in Philadelphia on November 6 to explore evolving evidence and management strategies. Register to attend in-person or online: ow.ly/2ZbL51018ww A CME/CE-accredited activity developed by GLC. #ThyroidEyeDisease #TED #MedEd

When disease progresses after frontline EGFR-TKI therapy, what factors should guide treatment decisions for patients with EGFR-mutated advanced NSCLC? During this live webinar series, expert faculty will review the evolving role of TROP2-directed ADCs and the clinical evidence supporting their use in the post-TKI setting. The program will also explore practical approaches to identifying appropriate candidates based on clinical and molecular characteristics, along with proactive strategies for recognizing and managing class-specific toxicities. Join the conversation and gain case-based insights on integrating TROP2-directed ADCs into personalized care: ow.ly/cFrA5100BB4 A CME/CE-accredited activity developed by GLC. #LungCancer #NSCLC #ThoracicOncology #Oncology #PrecisionMedicine #MedicalEducation

Still deciding whether to come to WHAV 2026? Don't miss the chance to connect with colleagues in person! From deeper connections with peers to conversations between sessions, there's a unique energy of collaboration that comes with gathering face-to-face. Hear more from event chair Barbara Dehn below. Seats are limited. Secure your spot today! Join us in NYC: ow.ly/9kFE50ZZtwu Register to attend in Pasadena: ow.ly/hhUo50ZZtwF #WHAV2026 #WomensHealth #MedicalEducation #CME

Primary FSGS can lead to progressive kidney function decline and dialysis. Could sparsentan influence treatment approaches? Explore the discussion on proteinuria reduction and eGFR decline: ow.ly/si9W50ZZpGJ #FSGS #Nephrology

Missed our first session? Join us tomorrow for the second session in our series exploring perioperative immunotherapy for resectable, locally advanced HNSCC. Gain practical insights into emerging clinical evidence, treatment sequencing, and case-based decision-making. Register now: ow.ly/rK5S50ZBA4L A CME/CE-accredited activity developed by GLC. #HNSCC #Oncology #Immunotherapy #CME

The 22nd Women's Health Annual Visit is coming to Pasadena. Join co-chairs Barbara Dehn , NP, and Anita L. Nelson, MD, plus expert faculty on November 13 at the Pasadena Convention Center for a full day of evidence-based education in women's health. Register now: reachmd.com/u/20116 #WHAV2026 #WomensHealth #MedicalEducation #CME #OBGYN #Pasadena

Over the years, the Women's Health Annual Visit (WHAV) has consistently brought together leading faculty to discuss pressing issues in women's health and present the latest data in clinical care. 2026 is no exception. This year, WHAV will feature a multidisciplinary group of speakers, each sharing cutting edge insights that clinicians can apply in their own practice immediately. Register for a spot before it's too late! Grab a seat for NYC: Sign up to attend in Pasadena: #WHAV2026 #WomensHealth #MedicalEducation #CME

How are TROP2-directed antibody-drug conjugates influencing treatment considerations for patients with EGFR-mutated advanced NSCLC after progression on frontline EGFR-TKI therapy? Join expert faculty for a live webinar series examining the evolving clinical evidence supporting TROP2-directed ADCs in the post-TKI setting. Through expert discussion and case-based learning, participants will explore emerging data that may influence treatment sequencing, discover how to identify appropriate candidates based on clinical and molecular characteristics, and review proactive strategies for monitoring and managing class-specific toxicities. Register to gain insights on integrating TROP2-directed ADCs into personalized treatment plans as this therapeutic landscape continues to evolve: ow.ly/LZAR50ZSRvY A CME/CE-accredited activity developed by GLC. #LungCancer #NSCLC #ThoracicOncology #Oncology #CancerCare #MedicalEducation

LAST CHANCE to register for the last session of our webinar series on first-line management of KRAS G12C–mutated advanced NSCLC. Hear expert discussion on biomarker testing, treatment sequencing, and clinical trial readiness. Register here: ow.ly/Gp8G50ZAI2n A CME/CE-accredited activity developed by GLC. #LungCancer #NSCLC #MedEd

The treatment landscape for KRAS G12C–mutated advanced NSCLC is advancing quickly. How can we close the gap between emerging biology and everyday practice? Gerard A. Silvestri, MD, MS will examine biomarker testing, first-line treatment selection, and strategies to prepare eligible patients for clinical trials in KRAS G12C–mutated advanced NSCLC in this upcoming live virtual broadcast: "Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care" 🗓️ Tuesday, September 30, 2026 🕟 4:30–5:15 PM EDT Save your seat: ow.ly/qY3x50ZPTh1 A CME/CE-accredited activity developed by GLC. #LungCancer #NSCLC #MedEd